Study guide

15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter

NCRA Oncology Data Specialist ODS-C

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters

1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish

2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws

2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority

3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance

3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance

4 Chapter 4: Registry Organization, Staffing & Information Systems

4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning

5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement

5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)

6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality

6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)

7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics

7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data

8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer

8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors

9 Chapter 9: Casefinding & Reportability

9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"

10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators

10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More

11 Chapter 11: Class of Case, Key Dates & Case Identifiers

11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them

12 Chapter 12: Follow-Up, Vital Status & Recurrence

12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary

13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade

13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables

14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules

14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules

15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018

15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples

16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS

16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation

15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter

Key Takeaways Explain This Topic AI

Prostate clinical T is based on digital rectal exam (T1c is a nonpalpable tumor found by needle biopsy), pathological T has no pT2 subcategories, and stage groups combine T, N, M, PSA and Grade Group.

Testicular pT is assigned from radical orchiectomy, N is based on node size (2 cm or less, more than 2–5 cm, more than 5 cm), and the S category uses post-orchiectomy LDH, hCG and AFP levels.

Kidney T1a is 4 cm or less, T1b more than 4–7 cm, T2a more than 7–10 cm, T2b more than 10 cm; T3a is renal vein, pelvicalyceal system, or perirenal or sinus fat invasion; and T4 extends beyond Gerota's fascia, including contiguous adrenal invasion.

Bladder Ta is noninvasive papillary, Tis is flat carcinoma in situ, T1 invades the lamina propria, T2a and T2b invade the inner and outer half of the muscularis propria, and T3 invades perivesical tissue.

Bladder N1 is a single node in the true pelvis, N2 is multiple true-pelvis nodes, and N3 is common iliac nodes; nonregional nodes are M1a.

Last updated: September 2026

  • Prostate (AJCC 8th, Chapter 58)
  • T categories
  • Clinical T (by DRE) Definition
  • cT1a Incidental finding in 5% or less of resected tissue (for example, TURP)
  • cT1b Incidental finding in more than 5% of resected tissue
  • cT1c Nonpalpable tumor identified by needle biopsy (for example, for an elevated PSA)
  • cT2a Palpable, confined, half of one side or less
  • cT2b More than half of one side, but not both sides
  • cT2c Both sides
  • cT3a Extraprostatic extension (one or both sides)
  • cT3b Seminal vesicle invasion

cT4 Fixed, or invades adjacent structures other than the seminal vesicles (external sphincter, rectum, bladder, levator muscles, pelvic wall)

  • Pathological T Definition
  • pT2 Organ confined. The 8th edition has no pT2 subcategories
  • pT3a Extraprostatic extension, or microscopic invasion of the bladder neck
  • pT3b Seminal vesicle invasion
  • pT4 Fixed, or invades adjacent structures other than the seminal vesicles

There is no pT1 . A tumor found on biopsy that is not palpable is cT1c , even if imaging shows it. Clinical T uses the DRE findings.

N and M

N1: regional nodes in the true pelvis (for example, obturator, internal and external iliac, sacral).

M1a: nonregional lymph nodes. M1b: bone. M1c: other sites, with or without bone disease.

Stage groups

  • Stage T N M PSA (ng/mL) Grade Group
  • I cT1a–c or cT2a, or pT2 N0 M0 Less than 10 1
  • IIA cT1a–c or cT2a, or pT2 N0 M0 10 to less than 20 1
  • IIA cT2b–c N0 M0 Less than 20 1
  • IIB T1–T2 N0 M0 Less than 20 2
  • IIC T1–T2 N0 M0 Less than 20 3 or 4
  • IIIA T1–T2 N0 M0 20 or more 1–4
  • IIIB T3–T4 N0 M0 Any 1–4
  • IIIC Any T N0 M0 Any 5
  • IVA Any T N1 M0 Any Any
  • IVB Any T Any N M1 Any Any

Grade Group comes from the Gleason score (Section 13.4): GG1 is 6 or less, GG2 is 3+4, GG3 is 4+3, GG4 is 8, and GG5 is 9–10. PSA and the Gleason items are also recorded as SSDIs .

Testis (AJCC 8th, Chapter 59)

Pathological T is assigned after radical orchiectomy . Clinical T uses cTX, cT0, cTis and cT4 only.

  • pT Definition
  • pTis Germ cell neoplasia in situ

pT1 Limited to the testis (including rete testis invasion) without lymphovascular invasion . For pure seminoma only: pT1a is less than 3 cm and pT1b is 3 cm or more

pT2 Lymphovascular invasion , or invasion of hilar soft tissue, epididymis, or the visceral mesothelial layer covering the tunica albuginea

  • pT3 Spermatic cord
  • pT4 Scrotum

N (clinical): cN1 is a node mass 2 cm or less; cN2 is more than 2 cm to 5 cm; cN3 is more than 5 cm. Pathological N also counts the number of nodes and extranodal extension.

M1a: non-retroperitoneal nodes or lung metastases. M1b: other visceral sites.

S (serum tumor markers after orchiectomy):

  • S LDH hCG (mIU/mL) AFP (ng/mL)
  • S1 Less than 1.5 × upper normal Less than 5,000 Less than 1,000
  • S2 1.5–10 × upper normal 5,000–50,000 1,000–10,000
  • S3 More than 10 × upper normal More than 50,000 More than 10,000

Stage groups:

IA: pT1 N0 M0 S0.

IB: pT2–pT4 N0 M0 S0.

IS: any pT, N0 M0, S1–S3 (persistently raised markers).

IIA, IIB, IIC: N1, N2, N3, with M0 and S0–S1.

IIIA: M1a with S0–S1.

IIIB: N1–N3 (M0) or M1a, with S2.

IIIC: N1–N3 (M0) or M1a, with S3; or any M1b.

Kidney (AJCC 8th, Chapter 60)

  • T Definition
  • T1a 4 cm or less, limited to the kidney
  • T1b More than 4 cm to 7 cm, limited to the kidney
  • T2a More than 7 cm to 10 cm, limited to the kidney
  • T2b More than 10 cm, limited to the kidney

T3a Extends into the renal vein or its segmental branches, invades the pelvicalyceal system , or invades perirenal or renal sinus fat but not beyond Gerota's fascia

  • T3b Extends into the vena cava below the diaphragm
  • T3c Extends into the vena cava above the diaphragm, or invades the wall of the vena cava
  • T4 Invades beyond Gerota's fascia , including contiguous extension into the ipsilateral adrenal gland

N1: regional node metastasis (there is no N2). M1: distant metastasis. A non-contiguous adrenal metastasis is M1 , not T4.

Stage groups: I is T1 N0; II is T2 N0; III is T3 N0, or T1–T3 N1; IV is T4 any N, or any M1.

Grade uses the WHO/ISUP nucleolar grade for clear cell and papillary renal cell carcinoma.

Urinary bladder (AJCC 8th, Chapter 62)

  • T Definition
  • Ta Noninvasive papillary carcinoma
  • Tis Urothelial carcinoma in situ, the flat tumor
  • T1 Invades the lamina propria (subepithelial connective tissue)
  • T2a Invades the inner half of the muscularis propria
  • T2b Invades the outer half of the muscularis propria
  • T3a Perivesical tissue, microscopically
  • T3b Perivesical tissue, macroscopically (extravesical mass)
  • T4a Prostatic stroma, seminal vesicles, uterus or vagina
  • T4b Pelvic wall or abdominal wall
  • N Definition
  • N1 Single node in the true pelvis (perivesical, obturator, internal and external iliac, or sacral)
  • N2 Multiple nodes in the true pelvis
  • N3 Common iliac node(s)

M1a: nonregional lymph nodes beyond the common iliac nodes. M1b: other distant sites.

Stage groups:

0a: Ta N0. 0is: Tis N0.

I: T1 N0. II: T2a–T2b N0.

IIIA: T3a–T4a N0, or T1–T4a N1.

IIIB: T1–T4a N2–N3.

IVA: T4b, or M1a. IVB: M1b.

Registry tips:

A TURBT gives clinical staging information; pathological T needs a cystectomy.

A TURBT specimen without muscularis propria cannot show whether the tumor invades muscle.

"Muscularis mucosae" invasion is not muscle-invasive disease. That is lamina propria, T1.

Renal pelvis and ureter (AJCC 8th, Chapter 61)

  • T Definition
  • Ta / Tis Noninvasive papillary / carcinoma in situ
  • T1 Subepithelial connective tissue
  • T2 Muscularis

T3 Renal pelvis: beyond the muscularis into peripelvic fat or renal parenchyma. Ureter: beyond the muscularis into periureteric fat

T4 Adjacent organs, or through the kidney into perinephric fat

N1: a single node 2 cm or less. N2: a single node larger than 2 cm, or multiple nodes.

Stage groups: 0a, 0is, I (T1), II (T2), III (T3), and IV (T4, any N1–N2, or M1).

Worked cases

Needle biopsy for PSA 6.2, no palpable nodule, Gleason 3+4 on biopsy, no imaging evidence of spread: cT1c N0 M0, PSA less than 10, GG2 , stage IIB .

Radical prostatectomy with extraprostatic extension, PSA 8, Gleason 4+3: pT3a N0 M0, GG3 , stage IIIB .

Orchiectomy shows seminoma, 2.5 cm, no lymphovascular invasion, normal markers after surgery, negative CT: pT1a N0 M0 S0 , stage IA .

Nephrectomy shows a 5.5 cm clear cell RCC with renal sinus fat invasion: pT3a . With N0 M0, stage III .

TURBT shows high-grade papillary urothelial carcinoma invading the lamina propria, with muscularis propria present and uninvolved: cT1 , stage I .

Loading diagram... Bladder T by depth of invasion